Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.35)
# 4,055
Out of 4,761 analysts
35
Total ratings
17.24%
Success rate
-27.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Overweight | n/a | $30.43 | - | 11 | Jan 29, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $83 | $39.70 | +109.07% | 2 | Dec 9, 2024 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $63.75 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $12.17 | +434.10% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.31 | - | 1 | Nov 8, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $7.28 | +202.20% | 3 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $1.92 | +629.17% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $47.91 | +123.34% | 4 | Aug 8, 2022 |
Beam Therapeutics
Jan 29, 2025
Upgrades: Overweight
Price Target: n/a
Current: $30.43
Upside: -
Legend Biotech
Dec 9, 2024
Reiterates: Overweight
Price Target: $83
Current: $39.70
Upside: +109.07%
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $63.75
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $12.17
Upside: +434.10%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.31
Upside: -
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $7.28
Upside: +202.20%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $1.92
Upside: +629.17%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $47.91
Upside: +123.34%